verified SJR 1,938 · Q1 • database Scopus / SJR & Web of Science indexed

United Kingdom · SAGE Publications Ltd

workspace_premium Q1 — Neurology (clinical) lock_open Open Access

Multiple Sclerosis

Multiple Sclerosis is a journal indexed in SJR in Neurology (clinical) and Neurology with an H index of 160. It has an SJR impact factor of 1,938 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,938.

Multiple Sclerosis focuses its scope in these topics and keywords: multiple, patients, sclerosis, ms, isolated, clinical, syndrome, progressive, courses, relapsing, ...

ISSN: 1352-4585

Publisher: SAGE Publications Ltd

Category: Neurology (clinical)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,938 Q1

H-index 160

Acceptance rate pie_chart

22% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,938

H-index

160

Docs (year)

259

Docs 3y

809

Total refs

6682

Cites 3y

3313

Citable 3y

668

Cites/Doc 2y

4.26

Ref/Doc

25.8

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Balo's concentric sclerosis: surviving normal myelin in a patient with a relapsing-remitting clinical course

Vitamin D and axonal injury in multiple sclerosis

Cytokines in multiple sclerosis: pro-inflammation or pro-remyelination?

Continuing optic nerve atrophy following optic neuritis: a serial MRI study

Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs

Colour vision impairment is associated with disease severity in multiple sclerosis

Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study

Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review

Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis

Caffeine and alcohol intakes have no association with risk of multiple sclerosis

Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study

Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity

SHOW MORE ARTICLES

Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial

A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis

Autoreactivity to myelin antigens related to HLA associations with multiple sclerosis

Astrocytopathy in Balo's disease

Association of vitamin D and multiple sclerosis in India

Are we in need of NEDA?

Advancing trial design in progressive multiple sclerosis

Acute anosmia in neuromyelitis optica spectrum disorder

Activity profile in multiple sclerosis: an integrative approach A preliminary report

a-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis

A systematic review of oral methotrexate for multiple sclerosis

FAQs

Multiple Sclerosis has an SJR of 1,938 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is not available (NPD). Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Multiple Sclerosis is 22%.

Multiple Sclerosis

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Multiple Sclerosis?

What is the APC / publication cost?

What is the acceptance rate?